Goldenrod Therapeutics has taken a significant step toward clinical development after completing the initial closing of a $6.5 million Series Seed preferred stock financing round. The Houston-based biotechnology company said the round was led by Ataxia Ventures and an affiliate of Fannin Partners, supporting the advancement of its lead program, 11h. The announcement positions Goldenrod as an emerging player in central nervous system drug development, with an initial focus on brain inflammation and Friedreich’s ataxia.
Financing Supports Clinical Readiness
The proceeds from the financing will be used to support manufacturing, formulation optimization, Investigational New Drug-enabling studies, and preparations for a Phase I clinical trial. Goldenrod plans to evaluate 11h first in Friedreich’s ataxia, a rare inherited neurodegenerative disease that causes worsening coordination, gait instability, speech impairment, and sensory dysfunction. The planned Phase I study is expected to assess safety, tolerability, pharmacokinetics, pharmacodynamic activity, and biomarkers linked to modulation of the PDE4 pathway.
Lead Program Targets Neuroinflammation
Goldenrod’s 11h program is built around a next-generation, orally available, brain-penetrant PDE4 inhibitor designed to address historical limitations of earlier drugs in the class. PDE4 has long been recognized as a regulator of neuroinflammation and neuronal signaling, but prior inhibitors have often faced challenges such as gastrointestinal side effects or insufficient exposure in the central nervous system. According to the company, 11h was engineered by researchers at the University of Nebraska Medical Center to improve brain penetration and tolerability, with preclinical work showing no evidence of significant emetic responses.
Friedreich’s Ataxia as First Indication
Friedreich’s ataxia remains an area of substantial unmet medical need despite the U.S. Food and Drug Administration’s approval of the first treatment for the condition in 2023. Many patients continue to experience disease progression, creating demand for therapies that work through distinct biological mechanisms. Goldenrod believes 11h could provide early evidence of biological activity in humans and help guide dose selection while supporting broader development across neurological and neuroinflammatory conditions.
Broader Development Potential
Although Friedreich’s ataxia is the company’s initial clinical focus, Goldenrod sees 11h as a platform-like opportunity across multiple CNS disorders. The company has identified potential applications in Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, substance use disorders, Batten disease, pain, and traumatic brain injury. A LinkedIn post associated with the announcement also highlighted encouraging preclinical data in multiple sclerosis, substance use disorders, Batten disease, and Alzheimer’s disease, while emphasizing the broader relevance of PDE4 biology in neuronal signaling and neuroinflammation.
Investor and Company Context
Ataxia Ventures’ involvement reflects investor interest in therapies targeting rare neurodegenerative diseases and broader CNS inflammation pathways. Goldenrod was founded through Fannin, a Houston-based life sciences development group that has helped advance multiple early-stage programs using a combination of investor and grant funding. The 11h program has also received support from grants provided by the National Institutes of Health and the U.S. Department of Defense, strengthening its translational development base.
Goldenrod expects to begin clinical development of 11h in 2027, marking a key milestone for the company’s lead asset and broader CNS strategy. The financing gives the company resources to move through the studies and operational steps needed before human testing can begin. If successful, the program could open a new path for treating Friedreich’s ataxia while laying groundwork for additional therapies targeting neuroinflammation and neuronal signaling across multiple neurological diseases.